Gilead shakes hands with generics to make the most of tough Indian IP market

US biotechnology company Gilead Sciences has announced licence deals with Indian drugmakers that will see generic versions of one of its headline products sold at lower prices in emerging markets. The arrangement between Gilead and the generic…

Unlock unlimited access to all IAM content